LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.38 per share a year ago.
Final Trade: LMAT, GOOGL, IBM, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth.
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2024 Earnings Conference Call October 33, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Rick Wise - Stifel Brett Fishbin - KeyBanc Jason Wittes - Roth Danny Stauder - Citizens JMP Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Ross Osborn - Cantor Fritzgerald Operator Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call.
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago.
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy
LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LeMaitre Vascular, Inc. (LMAT) Q2 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2024 Results Conference Call August 1, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Rick Wise - Stifel Jason Wittes - ROTH Danny Stauder - Citizens JMP Michael Sarcone - Jefferies Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Operator Welcome to the LeMaitre Vascular Q2 2024 Financial Results Conference Call.
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.37 per share a year ago.
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected.
LeMaitre: Further Upsides Supported By Longer Competitive Advantage Period
LeMaitre is a long-term compounder with mouth-watering economics and shareholder-friendly management. LMAT shares have rallied 45% since August '23, with increased dividends and improving fundamentals. Management has lengthened the reinvestment runway to deploy funds into the business at an advantage to drive further growth in corporate value.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's What You Should Know
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
